Surface Oncology, Inc. Common Stock
SURF
SURF was delisted on the 7th of September, 2023.
34 hedge funds and large institutions have $26.1M invested in Surface Oncology, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 4 increasing their positions, 16 reducing their positions, and 7 closing their positions.
25% more capital invested
Capital invested by funds: $20.9M → $26.1M (+$5.19M)
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
3% less funds holding
Funds holding: 35 → 34 (-1)
14% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 7
75% less repeat investments, than reductions
Existing positions increased: 4 | Existing positions reduced: 16
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$233K |
| 2 |
Squarepoint
New York
|
+$90.8K |
| 3 |
PAM
PVG Asset Management
Golden,
Colorado
|
+$45.2K |
| 4 |
BCM
Beddow Capital Management
Jackson,
Wyoming
|
+$41.6K |
| 5 |
HF
HRT Financial
New York
|
+$33.2K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BlackRock
New York
|
-$520K |
| 2 |
EC
EcoR1 Capital
San Francisco,
California
|
-$412K |
| 3 |
Millennium Management
New York
|
-$319K |
| 4 |
Victory Capital Management
San Antonio,
Texas
|
-$152K |
| 5 |
Jacobs Levy Equity Management
Florham Park,
New Jersey
|
-$104K |
SURF Hedge Fund Activity: Q4 2019 in Review
34 of the 5,075 institutional investors tracked by Wall St. Rank reported a position in Surface Oncology, Inc. Common Stock (SURF) for Q4 2019, worth a combined $26.1M — up 25% from $20.9M a quarter earlier.
Sellers outnumbered buyers: 7 funds closed out of SURF and 6 opened new positions — a net loss of 1 holder — while 16 trimmed existing stakes and 4 added.
The largest buyer was Renaissance Technologies, adding an estimated $233K. The largest seller was BlackRock, cutting an estimated $520K.
- 34 institutional investors held Surface Oncology, Inc. Common Stock (SURF) as of Q4 2019, down from 35 in Q3 2019.
- Funds reported $26.1M of Surface Oncology, Inc. Common Stock stock for Q4 2019, up 25% quarter-over-quarter.
- 6 funds opened new Surface Oncology, Inc. Common Stock positions in Q4 2019 and 7 closed out, a net change of -1 holder.
- The largest Surface Oncology, Inc. Common Stock buyer in Q4 2019 was Renaissance Technologies, an estimated $233K added.
- The largest Surface Oncology, Inc. Common Stock seller in Q4 2019 was BlackRock, an estimated $520K sold.
Based on aggregated 13F filings for Q4 2019.